The organization emphasizes patient access alongside research, including a $2.5 million grant to study expanding veterans’ access to blood cancer clinical trials across 12 VA facilities.

Blood Cancer United reports extensive patient-support activity, with over 69,000 individual awards totaling $162 million in the prior year and a Medical Debt Case Management Program that resolved over $5.1 million in medical debt as of September 2025.

Blood Cancer United, formerly The Leukemia & Lymphoma Society, announced a new funding round that brings its cumulative research funding to over $2 billion to date, aimed at advancing cures and improving quality of life for people with blood cancer and their families.

Researchers praised the impact of the funding, including experts from MSK, Stanford, Moffitt, and UPenn, underscoring a collaborative, translational approach to the funded work.

The release stresses adapting to disrupted federal funding and filling critical gaps to sustain momentum, highlighting collaboration, AI and big data, and global partnerships.

In addition, the fund backs Stanford’s Myeloma CAR-T/immunotherapy program and research to improve outcomes in myeloid diseases through targeting RAS and other approaches.

TAP is highlighted as a strategic venture philanthropy initiative that sustains active collaborations and accelerates breakthrough discoveries.

The organization aims to be the largest private funder of blood cancer research and notes ongoing efforts to expand access to trials and care while reducing financial barriers.

The organization now oversees a Therapy Acceleration Program (TAP) with 18 active partnerships spanning academic institutes and biopharmaceutical companies to speed up development.

Since its founding, the group has surpassed $2 billion in funding, with more than $269 million committed to multi-year grants supporting over 250 academic research projects and 18 TAP partnerships.

Highlighted projects include a $5 million AML genetics study at UPenn, a $6.5 million ERADICATE alliance for follicular lymphoma, Auron Therapeutics’ AI-driven AML/MDS work, and Stanford and UPenn researchers advancing myeloma, RAS inhibition, and SRSF2 mutation studies.

Funding supports early-, mid-, and late-stage research, including foundational science, AI, big data analytics, and global collaborations to move treatments toward FDA approval and accelerate discovery.